etelcalcetide; velcalcetide (Parsabiv)
Jump to navigation
Jump to search
Indications
- secondary hyperparathyroidism in adults with chronic renal failure on hemodialysis
Dosage
- start 5 mg IV bolus 3 times per week after hemodialysis
- individualize maintenance dose by titration based on serum parathyroid hormone and corrected serum calcium
- dosage range: 2.5-15 mg IV 3 times per week.
- 2.5 mg/0.5 mL, 5 mg/mL & 10 mg/2mL single use vials
Adverse effects
Mechanism of action
More general terms
References
- ↑ Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Block GA, Bushinsky DA, Cheng S Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28097356
Block GA, Bushinsky DA, Cunningham J et al Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146-155. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28097355 - ↑ Parsabiv. HIGHLIGHTS OF PRESCRIBING INFORMATION https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208325Orig1s000Lbledt.pdf